Literature DB >> 2476781

DL and D sotalol decrease defibrillation energy requirements.

M Wang1, P Dorian.   

Abstract

We examined the acute effects of intravenous DL and D sotalol on the energy requirements for internal defibrillation (DF) in 44 dogs anesthetized with pentobarbital (n = 18), enflurane (n = 8), and fentanyl (n = 18). Multiple shocks of varying energies were applied through left and right ventricular epicardial patch electrodes to relate delivered energy to percent success in DF. The energies required for 50% success in DF (E) were estimated by logistic regression. DL or D sotalol was administered in a loading (4 mg/kg over 10 min) and maintenance (1.5 mg/kg/hr) infusion and the energy--success curve was again measured 30 minutes after drug administration. The effect of DL and D sotalol on E50 was compared to controls given saline. Both DL and D sotalol significantly lowered E50 by 16% +/- 14% (P less than 0.05) and 24.5% +/- 8.2% (P less than 0.05), respectively, in fentanyl anesthetized animals; this was accompanied by a 22% +/- 8% (P less than 0.05) and 16% +/- 5% (P less than 0.01) increase in ventricular effective refractory period (VERP), respectively. In pentobarbital anesthetized dogs, DL and D sotalol decreased E50 by 16% +/- 27% (P = ns) and 11% +/- 16% (P less than 0.05), respectively, and were associated with a 23% +/- 5% (P less than 0.01) and 12 +/- 4% (P less than 0.05) prolongation of VERP. DL and D sotalol decrease defibrillation energy requirements, possibly as a result of their Class III antiarrhythmic drug action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476781     DOI: 10.1111/j.1540-8159.1989.tb06157.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  9 in total

Review 1.  Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation.

Authors:  Yadavendra S Rajawat; Darryl Dias; Edward P Gerstenfeld; Sanjay Dixit; Bindi Shah; Andrea M Russo; Francis E Marchlinski
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

Review 2.  Combining antiarrhythmic drugs and implantable devices therapy: benefits and outcome.

Authors:  M Santini; C Pandozi; R Ricci
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

3.  Incidence and clinical predictors of low defibrillation safety margin at time of implantable defibrillator implantation.

Authors:  Zhongwei Cheng; Mintu Turakhia; Ronald Lo; Anurag Gupta; Paul C Zei; Henry H Hsia; Amin Al-Ahmad; Paul J Wang
Journal:  J Interv Card Electrophysiol       Date:  2012-03-06       Impact factor: 1.900

4.  Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation.

Authors:  X Q Qi; D Newman; P Dorian
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

5.  Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.

Authors:  Anna Nergärdh; Rolf Nordlander; Mats Frick
Journal:  Clin Cardiol       Date:  2006-02       Impact factor: 2.882

Review 6.  Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

7.  Induction by direct current pulse versus 50-Hz pacing on ventricular fibrillation and defibrillation.

Authors:  Hoong Sern Lim; Sharon Flannigan; Howard Marshall
Journal:  J Interv Card Electrophysiol       Date:  2010-05-12       Impact factor: 1.900

Review 8.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 9.  Effect of drugs on defibrillation capacity.

Authors:  Anna Legreid Dopp; John M Miller; James E Tisdale
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.